Tsumura & Co
TSE:4540

Watchlist Manager
Tsumura & Co Logo
Tsumura & Co
TSE:4540
Watchlist
Price: 4 201 JPY 0.14% Market Closed
Market Cap: 322.5B JPY

EV/EBIT
Enterprise Value to EBIT

9.5
Current
9.9
Median
15.5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
9.5
=
Enterprise Value
316.3B JPY
/
EBIT
33.3B JPY
Market Cap EV/EBIT
JP
Tsumura & Co
TSE:4540
319B JPY 9.5
US
Eli Lilly and Co
NYSE:LLY
699.5B USD 42.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
368.8B USD 16.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 14.3
CH
Roche Holding AG
SIX:ROG
208.7B CHF 12.1
UK
AstraZeneca PLC
LSE:AZN
167.6B GBP 192.8
CH
Novartis AG
SIX:NOVN
186.3B CHF 14.1
US
Merck & Co Inc
NYSE:MRK
206.3B USD 9.7
IE
Endo International PLC
LSE:0Y5F
162.4B USD 650.8
FR
Sanofi SA
PAR:SAN
119.8B EUR 13.3
EBIT Growth EV/EBIT to Growth
JP
Tsumura & Co
TSE:4540
Average EV/EBIT: 1 698
9.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.5
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.1
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.3
16%
0.9
CH
Roche Holding AG
SIX:ROG
12.1
9%
1.3
UK
AstraZeneca PLC
LSE:AZN
192.8
21%
9.2
CH
Novartis AG
SIX:NOVN
14.1
8%
1.8
US
Merck & Co Inc
NYSE:MRK
9.7
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
FR
Sanofi SA
PAR:SAN
13.3
14%
0.9

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A